In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $23.00.

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President Donald Trump’s trade war continues to escalate with new tariffs.

April 3 (Reuters) - British pharmaceutical giant GlaxoSmithKline (GSK.L), opens new tab and rival Pfizer (PFE.N), opens new tab have agreed to end a lawsuit that alleged Pfizer's respiratory ...

Pfizer shares fell 1.32% after reports U.S. prosecutors are investigating claims from GSK about the timing of Pfizer’s COVID-19 vaccine. Pfizer denies allegations of delaying vaccine results for ...

Pfizer is currently a high-yield quality stock trading at reasonable valuations, indicating a margin of safety that surely curtails investment risks. With the stock market subject to bouts of ...

March 19 (Reuters) - Drugmaker Pfizer (PFE.N), opens new tab has sold its entire stake in Haleon (HLN.L), opens new tab for about 2.5 billion pounds ($3.24 billion) to institutional investors and ...

(Reuters) -Pfizer will sell its remaining stake in British consumer healthcare group Haleon, the companies said on Tuesday. Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon ...

British drugmaker GSK told Manhattan prosecutors that a former employee told colleagues Pfizer held back positive results until after the 2020 election. But the former employee, who worked at both ...

Pfizer offers a substantial 6.7% dividend yield and has increased its dividend for 16 consecutive years. The stock trades at a forward P/E of just 8.7, close to historical lows. Despite policy ...

The ad concludes by directing viewers to Pfizer’s VaxAssist website to find and schedule a vaccine. Though the company’s logo is prominently displayed in the final shots of the ad, the ...